3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
6
Lung Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
3
Pancreatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Gastrointestinal Neoplasms
2
Uterine Cervical Neoplasms
1
Support of the Family as a Caregiving System
1
Stomach Neoplasms
1
Sarcoma
1
Quality of Life
1
Pseudomyxoma Peritonei
1
Paranasal Sinus Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Oropharyngeal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Mixed Dementias
1
Mesothelioma, Malignant
1
Meningeal Carcinomatosis
1
Maxillary Sinus Neoplasms
1
Malignant Female Reproductive System Neoplasm
1
Lymphoma, Follicular
1
Localized Head and Neck Carcinoma
1
Interventions
Cisplatin
28
Pemetrexed
24
pembrolizumab
12
Nivolumab
10
Carboplatin
9
atezolizumab
7
Gemcitabine
7
Cyclophosphamide
7
durvalumab
6
Drug Therapy
6
sodium thiosulfate
5
Radiotherapy, Intensity-Modulated
5
tremelimumab
4
aldesleukin
4
Radiotherapy
4
Interleukin-2
4
sargramostim
3
Vinorelbine
3
Platinum
3
Photochemotherapy
3
Ipilimumab
3
Doxorubicin
3
Dihematoporphyrin Ether
3
Chemotherapy, Adjuvant
3
Cerebral Decortication
3
vatalanib
2
regorafenib
2
niraparib
2
lenvatinib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma, Malignant
×
Referral and Consultation
×
Clear all
NCT01126346
2018-07-03
HOPE
Wake Forest University Health Sciences
Phase NA
Completed
10 enrolled